SCOLR Pha Form 4 March 16, 2							
FORM	14		OMB APPROVAL				
	UNITED STAT	ES SECURITIES AND EXCHANGE Washington, D.C. 20549	COMMISSION OMB Number: 3235-0287				
Check th if no lon	ger	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	Expires: January 31, 2005				
subject to	o SIAIEMENI	OF CHANGES IN BENEFICIAL OW	NERSHIP OF Estimated average burden hours per				
	Section 16. SECURITIES Form 4 or						
Form 5	Filed pursuant t	o Section 16(a) of the Securities Exchan	response 0.5 ge Act of 1934,				
obligatio may con	tinue. Section 17(a) of th	e Public Utility Holding Company Act of					
See Instr	uction 30(h) of the Investment Company Act of 19	940				
1(b).							
(Print or Type)	Responses)						
	Address of Reporting Person <u>*</u> MICHAEL N	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer				
		SCOLR Pharma, Inc. [DDD]	(Check all applicable)				
(Last)	(First) (Middle)	3. Date of Earliest Transaction					
3625 132N	D AVENUE SE SUITE	(Month/Day/Year) 03/16/2007	X_ Director 10% Owner Officer (give title Other (specify				
400			below) below)				
	(Street)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check				
		Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person				
BELLEVU	E, WA 98006		Form filed by More than One Reporting Person				
(City)	(State) (Zip)	Table I - Non-Derivative Securities Ac	equired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)	any	eemed 3. 4. Securities Acquired tition Date, if Transaction(A) or Disposed of (D Code (Instr. 3, 4 and 5) (h/Day/Year) (Instr. 8)	SecuritiesForm: DirectIndirectBeneficially(D) orBeneficialOwnedIndirect (I)OwnershipFollowing(Instr. 4)(Instr. 4)				
		(A) or Code V Amount (D) Price	Reported Transaction(s) (Instr. 3 and 4)				
Common Stock	03/16/2007	P 30,000 A \$ 2.32	428,285 D				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: SCOLR Pharma, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
TAGLICH MICHAEL N 3625 132ND AVENUE SE SUITE 400 BELLEVUE, WA 98006	Х						
Signatures							
Michael N. Taglich by Alan M. Mitchel, Attorney-in-Fact			03/16/20	007			
<u>**</u> Signature of Reporting Person		Date					
Evalenction of Deenen							

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.